CAMBRIDGE, Massachusetts, January 23, 2012 /PRNewswire/ --
- Virtify sponsors session where pharmaceutical senior executives share insights and discuss challenges of meeting the July 2, 2012 EMA EudraVigilance Medicinal Products Dictionary reporting requirements
Virtify, Inc., will host an online roundtable on January 25, 10 AM EST to facilitate an open discussion by senior executives from four multinational pharmaceutical companies on the specific challenges and steps they are taking to comply with the July 2, 2012 EVMPD reporting mandate. A Q & A session will follow.
Roundtable panelists will include John W Kiser, of Abbott Laboratories USA, Dr Jorg Lautz, of Grunenthal GmbH, Germany, Gordon Topping from the Takeda Global R&D Centre (Europe), UK, and Richard Eddershaw of GSK R&D, UK. Dr. Andrew Marr, Managing Director of Marr Consultancy will moderate the discussion.
"This roundtable will provide an excellent opportunity for the industry to share lessons learned, discuss approaches to address the unknowns which still exist, and exchange other information for addressing this challenging new requirement in a tight timeframe," said Satish Tadikonda, CEO and founder of Virtify. "In our conversations with many different drug sponsors that are working to respond to this mandate, we realized that it really makes sense to facilitate this kind of productive exchange."
Attendees can sign up to listen in to the roundtable discussion and submit questions to the panel by registering at http://www.virtify.com/news-events/events/
Virtify is the market leader in Structured Content Management software solutions for life sciences. Organizations rely on Virtify solutions to reduce time-to-market, risk, and costs by managing and automating the complex regulatory compliance and content exchange requirements throughout the product life cycle. Virtify's easy-to-use software suite is the industry's only solution to provide a secure, collaborative, web-based environment for managing regulated content throughout the entire continuum - from pre-clinical through product registration to commercialization.
The company's EVMPD software enables organizations to address the EU's July 2012 submission deadline for additional EVMPD data and is part of its suite of structured content management based solutions. The software helps customers collect, validate, and manage the relevant data and provides the capability to submit the data electronically to the EMA including the ability to efficiently provide updates on product data when product information is changed. By applying the Virtify structured content approach, all data gathered is optimized for re-use across the organization. http://www.virtify.com
SOURCE Virtify, Inc.